Speakers:
Manuel Porcar Miralles, PhD in Biological Sciences and a senior researcher at the University of Valencia, founder of DARWIN Bioprospecting Excellence
Pauliina Halimaa, Managing Director, PhD, Biosafe
Microbial product development starts with discovery, but promising biology alone does not make a product market-ready. Strains need to be suitable for development, scalable in practice, safe for the intended use and able to meet regulatory expectations in the target market.
In this joint webinar, Darwin Bioprospecting and Biosafe will walk through the critical decision points from strain discovery to regulatory success. The session will focus on what companies should consider early: strain selection, screening, characterisation, safety signals, documentation needs and regulatory viability.
Speakers
Manuel Porcar Miralles holds a PhD in Biological Sciences and is a senior researcher at the University of Valencia. He specializes in bioprospecting and microbiology and has been a former member of the Spanish Commission for Biosafety and the Institut Pasteur. He is the author of more than 100 scientific publications and patents.
In 2021, he received the Ig Nobel Prize for his research on the bacteria found in discarded chewing gum stuck to pavements.
In 2016, together with Cristina Vilanova, he founded DARWIN Bioprospecting Excellence, a microbial biotechnology company based at the Parc Científic de la Universitat de València. The company specializes in advanced bioprospecting, transforming microbial diversity into innovative industrial solutions.
Pauliina Halimaa is Managing Director of Biosafe and works at the interface of biotechnology, food and feed safety, regulatory strategy and market access. In the webinar, she will discuss how companies can assess the regulatory viability of microbial strains early and avoid common development risks linked to safety, characterisation and documentation.
Organized by:
More information:
Pauliina Halimaa, Managing Director, Biosafe
